Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient
in a multicenter Phase II clinical trial of the investigational compound
PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic
disorder characterized by progressive muscle degeneration and weakness.
Pfizer Inc. invites investors and the general public to listen to a
webcast of a discussion with Albert Bourla, Group President, Vaccines,
Oncology and Consumer Healthcare Business, at the Credit Suisse 2014
Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m.
Mountain Standard Time.
Pfizer Inc. invites investors and the general public to view and listen
to a webcast of a presentation by Mikael Dolsten, President, Worldwide
Research and Development, at the 33 rd Annual J.P. Morgan
Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific
The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc.
that at this time there is no plan for an Oncologic Drugs Advisory
Committee meeting for IBRANCE ® (palbociclib).
Pfizer continues to have an open and productive dialogue with the FDA as
the application for IBRANCE advances.
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug
Administration (FDA) has granted accelerated approval of TRUMENBA ®
(meningococcal group B vaccine) for active immunization to prevent
invasive disease caused by Neisseria meningitidis serogroup B in
individuals 10 through 25 years of age.
Sign-up for Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults investment picks
Pfizer Inc. (NYSE:PFE) announced today top-line results from a
double-blind Phase 3 study evaluating pregabalin controlled-release (CR)
formulation in adult patients with postherpetic neuralgia (pain after
shingles or PHN). The results show that pregabalin CR resulted in a
statistically significant positive effect compared to placebo in the
primary endpoint, time to loss of therapeutic response (LTR) in pain
Pfizer shares (PFE) rose 1.4% in after-hours trade Thusday after the blue-chip drug maker said it has authorized a new $11 billion share buyback program, to be "utilized over time." That is in addition to the $1.3 billion left in its previous repurchase program.
Pfizer Inc. (NYSE: PFE )
has notified Pain Therapeutics, Inc. (NASDAQ: PTIE )
that it has decided to discontinue its agreement to develop and
commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an
investigational extended-release oral formulation of oxycodone.
By Angela Chen
OPKO will get upfront payment of $295 million and is eligible for up to $275 million more
Pfizer Inc. and OPKO Health Inc. have partnered to develop and commercialize an OPKO treatment for growth-hormone deficiency that could replace daily injections with weekly ones.
By Angela Chen
The U.S. Food and Drug Administration isn't planning an advisory committee meeting at this time to evaluate Pfizer Inc.'s experimental breast-cancer treatment, despite the drug having received priority-review status in October, the company said Thursday.
Pfizer's stock (PFE) fell 1.6% in premarket trade Monday, after the blue-chip drug maker lowered its 2014 profit outlook following its agreement to team up with Germany's Merck KGaA to develop new cancer treatments.
Pfizer Inc. (NYSE:PFE) today announced the publication of a clinical
study in the Journal of Clinical Psychiatry showing comparable
sexual function in adult patients diagnosed with major depressive
disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg
and 100mg doses versus placebo.
As part of its ongoing dedication to education and powering California’s
future, Pacific Gas and Electric Company (PG&E) today announced the
launch of its fourth annual PG&E
Bright Minds™ Scholarship program .
Pacific Gas and Electric Company (PG&E) today affirmed its commitment to
transparency and accountability and encouraged the California Public
Utilities Commission (CPUC) to adopt new protocols for open access to
communications between the Commission and all parties who are
interacting with the CPUC.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.